Next Science Limited Stock Performance

NXSCF Stock  USD 0.01  0.01  50.00%   
The company secures a Beta (Market Risk) of 2.41, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Next Science will likely underperform. At this point, Next Science Limited has a negative expected return of -0.12%. Please make sure to verify Next Science's downside variance, as well as the relationship between the kurtosis and day typical price , to decide if Next Science Limited performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Next Science Limited has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest fragile performance, the Stock's fundamental indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders. ...more
Begin Period Cash Flow19.9 M
Total Cashflows From Investing Activities-716.8 K
  

Next Science Relative Risk vs. Return Landscape

If you would invest  11.00  in Next Science Limited on November 10, 2025 and sell it today you would lose (9.50) from holding Next Science Limited or give up 86.36% of portfolio value over 90 days. Next Science Limited is currently producing negative expected returns and takes up 18.6361% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Next, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days.
  Expected Return   
       Risk  
Assuming the 90 days horizon Next Science is expected to under-perform the market. In addition to that, the company is 22.94 times more volatile than its market benchmark. It trades about -0.01 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.12 per unit of volatility.

Next Science Target Price Odds to finish over Current Price

The tendency of Next Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 0.01 90 days 0.01 
close to 99
Based on a normal probability distribution, the odds of Next Science to move above the current price in 90 days from now is close to 99 (This Next Science Limited probability density function shows the probability of Next Pink Sheet to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon the pink sheet has the beta coefficient of 2.41 . This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Next Science will likely underperform. Moreover Next Science Limited has an alpha of 1.0409, implying that it can generate a 1.04 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Next Science Price Density   
       Price  

Predictive Modules for Next Science

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Next Science Limited. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Next Science's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.000.0218.66
Details
Intrinsic
Valuation
LowRealHigh
0.000.0118.65
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.010.010.02
Details

Next Science Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Next Science is not an exception. The market had few large corrections towards the Next Science's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Next Science Limited, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Next Science within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
1.04
β
Beta against Dow Jones2.41
σ
Overall volatility
0.02
Ir
Information ratio 0.05

Next Science Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Next Science for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Next Science Limited can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Next Science Limited generated a negative expected return over the last 90 days
Next Science Limited has high historical volatility and very poor performance
Next Science Limited has some characteristics of a very speculative penny stock
The company reported the revenue of 8.95 M. Net Loss for the year was (9.35 M) with profit before overhead, payroll, taxes, and interest of 6.94 M.
Next Science Limited has accumulated about 11.06 M in cash with (8.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 53.0% of the company outstanding shares are owned by corporate insiders

Next Science Fundamentals Growth

Next Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Next Science, and Next Science fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Next Pink Sheet performance.

About Next Science Performance

By analyzing Next Science's fundamental ratios, stakeholders can gain valuable insights into Next Science's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Next Science has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Next Science has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia. Next Science Limited was founded in 2012 and is headquartered in Chatswood, Australia. Next Science operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.

Things to note about Next Science Limited performance evaluation

Checking the ongoing alerts about Next Science for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Next Science Limited help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Next Science Limited generated a negative expected return over the last 90 days
Next Science Limited has high historical volatility and very poor performance
Next Science Limited has some characteristics of a very speculative penny stock
The company reported the revenue of 8.95 M. Net Loss for the year was (9.35 M) with profit before overhead, payroll, taxes, and interest of 6.94 M.
Next Science Limited has accumulated about 11.06 M in cash with (8.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 53.0% of the company outstanding shares are owned by corporate insiders
Evaluating Next Science's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Next Science's pink sheet performance include:
  • Analyzing Next Science's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Next Science's stock is overvalued or undervalued compared to its peers.
  • Examining Next Science's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Next Science's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Next Science's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Next Science's pink sheet. These opinions can provide insight into Next Science's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Next Science's pink sheet performance is not an exact science, and many factors can impact Next Science's pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Next Pink Sheet analysis

When running Next Science's price analysis, check to measure Next Science's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Next Science is operating at the current time. Most of Next Science's value examination focuses on studying past and present price action to predict the probability of Next Science's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Next Science's price. Additionally, you may evaluate how the addition of Next Science to your portfolios can decrease your overall portfolio volatility.
Bonds Directory
Find actively traded corporate debentures issued by US companies
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope